ICYMI: The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms. lnkd.in/egjCkDdR
📣 Latest pod out now! This week:
🔹 Ultomiris gains accelerated approval;
💉 Alzheimer vaccine Fast Tracked;
🔸 Retatrutide demonstrates significant weight lose;
🦠 Hibsago approved for hepatitis B; &
🤢 GLP-1-indicued vomiting reduced with tradipitant.
empr.com/news/mpr-weekly-dos…
The FDA has extended the review period for mitapivat for the treatment of sickle cell disease; the Agency needs additional time to to determine whether a Risk Evaluation and Mitigation Strategy is necessary. empr.com/news/fda-extends-mi…
Eli Lilly’s next gen triple hormone receptor agonist, retatrutide, was shown to achieved significantly greater body weight reduction vs Ozempic. empr.com/news/retatrutide-su…
Two recent Right of Access cases highlight how noncompliance with patient record access timelines can lead to substantial financial penalties. #LawUpdate empr.com/news/legal-update-p…
Petosemtamab in combination with pembrolizumab shows promised in phase 3 trial as first-line treatment. empr.com/news/petosemtamab-p…
Lowering the age of vaccination improves the total number of people protected against HPV, study finds. empr.com/news/idsa-earlier-i…
If approved, this topical mTOR inhibitor would become the first FDA-approved therapy for children and adults with microcystic lymphatic malformations. empr.com/news/fda-priority-r…
Eli Lilly’s next gen triple hormone receptor agonist, retatrutide, was shown to achieved significantly greater body weight reduction vs Ozempic. empr.com/news/retatrutide-su…
Dr Hubert H. Fernandez discusses how the newly approved D1/D5 agonist Juvmo (tavapadon) fits into current treatment paradigms for adult Parkinson disease. empr.com/news/juvmo-tavapado…
Trial results will form the basis for a regulatory submission to use Elrexfio treatment earlier in relapsed or refractory multiple myeloma therapy. empr.com/news/elranatamab-pf…
Topline phase 3 data show tradipitant significantly reduced GLP-1–associated vomiting and severe nausea in overweight or obese adults. empr.com/news/tradipitant-ph…
Florida’s Hillsborough County remains a dengue hot spot and cooler weather may offer only a short break. #DengueOutbreak empr.com/news/florida-dengue…
The FDA approved the PARP inhibitor talazoparib with enzalutamide for adults with HRR gene-mutated metastatic castration-sensitive prostate cancer. #DrugApprovals empr.com/news/fda-approves-t…
There was fast uptake for Wegovy pill prescriptions after launch, meanwhile the rates for injectable weight management prescriptions did not slow down. empr.com/news/early-uptake-w…
With this approval, patients with CD may now initiate Skyrizi subcutaneously via an on-body injector induction pack or receive it as an intravenous infusion. empr.com/news/fda-approves-s…
The newly approved Zilbrysq autoinjector provides an alternative to the prefilled syringe for daily self-administration. empr.com/news/fda-approves-z…
MPR spoke with the global lead Juvmo investigator, Hubert H. Fernandez, MD, who talks about the key takeaways for clinicians considering the newly approved Parkinson disease Tx. empr.com/news/juvmo-tavapado…
Michelle Min, MD, MS, who presented at the Fall Clinical Dermatology Conference, met with the MPR team to discuss multidisciplinary collaboration in the treatment of cutaneous lupus. empr.com/reports/video-curre…
